<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01680211</url>
  </required_header>
  <id_info>
    <org_study_id>OL-S-OB-LP/03-12</org_study_id>
    <secondary_id>CTRI/2012/05/002678</secondary_id>
    <nct_id>NCT01680211</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Herbal Supplements in Prediabetic and Mild to Moderate Hyperlipidemic Patients</brief_title>
  <official_title>Efficacy and Safety Study of Herbal Supplements (SR-L-01, SR-B-01 and SI-S-01) in the Management of Prediabetes and Mild to Moderate Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olive Lifesciences Pvt Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Olive Lifesciences Pvt Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of this study is to determine the safety and efficacy of administration of herbal
      supplements (Salacia leaf extract, Salacia root extract and Sesame seed extract) for 6 weeks
      in the management of prediabetes and mild to moderate hyperlipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Blood Sugar and lipid profiles</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>Change in of blood sugar out come will be measured by Fasting Blood Sugar (FBS), Oral Glucose Tolerance Test (OGTT) and Postprandial Blood Sugar (PPBS). Change in lipid profiles are measured by Low Density Lipoprotein (LDL), Very Low Density Lipoprotein (VLDL), High Density Lipoprotein (HDL) and Total Cholesterol (TC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory evaluations</measure>
    <time_frame>0 and week 6</time_frame>
    <description>Electrocardiography (ECG), haematology (Complete Blood Count), biochemical tests (blood urea, and serum creatinine), liver function tests and urine routine analysis</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Prediabetes</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Salacia bark extract (SR-B-01) and TLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules containing 250mg of salacia bark extract,two times a day along with Therapeutic Lifestyle Change (TLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sesame seeds extract (SI-S-01) and TLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules containing 250mg of sesame seed extract,two times a day along with Therapeutic Lifestyle Change (TLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salacia leaf extract (SR-L-01) and TLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules containing 250mg of salacia leaf extract,two times a day along with Therapeutic Lifestyle Change (TLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and TLC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules containing 250mg of placebo,two times a day along with Therapeutic Lifestyle Change (TLC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Salacia bark extract</intervention_name>
    <arm_group_label>Salacia bark extract (SR-B-01) and TLC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Salacia leaf extract</intervention_name>
    <arm_group_label>Salacia leaf extract (SR-L-01) and TLC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sesame seed extract</intervention_name>
    <arm_group_label>Sesame seeds extract (SI-S-01) and TLC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>TLC</intervention_name>
    <description>Lifestyle changes include diet, exercise, weight loss, etc.</description>
    <arm_group_label>Salacia bark extract (SR-B-01) and TLC</arm_group_label>
    <arm_group_label>Sesame seeds extract (SI-S-01) and TLC</arm_group_label>
    <arm_group_label>Salacia leaf extract (SR-L-01) and TLC</arm_group_label>
    <arm_group_label>Placebo and TLC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo and TLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. As per ATP III guidelines: Baseline LDL ranging 160-189 mg/dL, TC &gt;200 mg/dL and with
             no or one of the below risk factors

               -  Current cigarette smoking

               -  Family history of premature Coronary Heart Disease(CHD); in male first degree
                  relative &lt;55 years; in female first degree relative &lt;65 years)

               -  Hypertension (BP &gt;140/90 mmHg or on antihypertensive medication)

               -  Low HDL-C (&lt;40 mg/dL)

               -  Age (men &gt; 40 years)

          2. Impaired glucose tolerance (2-hour post 75 g OGTT glucose levels in the range of ≥140
             to ≤ 200 mg/dL)

          3. Impaired fasting sugar (Fasting blood sugar levels in the range of ≥ 100 to ≤125
             mg/dL)

          4. Being mentally competent and able to understand all study requirements and sign the
             informed consent form.

        Exclusion Criteria:

          1. Patients with severe liver, renal, cardiac or brain diseases.

          2. Pregnant or lactating women or women of child bearing potential whom are not
             practicing a reliable form of birth control (either with IUD or with stable usage of
             oral contraceptives).

          3. Unable to complete follow up.

          4. Subjects on any medication that would affect evaluation like Statins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K R Raveendra, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Srinivasa Clinic &amp; Diabetic Care Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Srinivasa Clinic &amp; Diabetic Care Center</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560050</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2012</study_first_submitted>
  <study_first_submitted_qc>September 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2012</study_first_posted>
  <last_update_submitted>September 3, 2012</last_update_submitted>
  <last_update_submitted_qc>September 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Sugar,</keyword>
  <keyword>Lipoproteins,</keyword>
  <keyword>Salacia,</keyword>
  <keyword>Sesame,</keyword>
  <keyword>Prediabetes,</keyword>
  <keyword>Hyperlipidemia,</keyword>
  <keyword>Herbal supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

